Michael McGrail

A partner in Goodwin’s Technology group, Michael McGrail’s practice includes the representation of company and investor clients in a full range of corporate legal projects, including mergers and acquisitions, private financings, corporate partnerships, and technology licensing. He counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. Michael is fluent in German, and a significant portion of his practice is devoted to international transactions.

M&A Transactions:

• Represented Tillotts in its joint venture with TVM Capital Life Science*
• Represented Baylis in its acquisition by Boston Scientific*
• Represented BASF in its acquisition of Becker Underwood* 
• Represented TYRX in its acquisition by Medtronic* 
• Represented HyperBranch Medical Technology in its acquisition by Stryker*
• Represented Image Stream Medical in its acquisition by Olympus* 
• Represented Impact Instrumentation is its acquisition by ZOLL Medical*
• Represented SuppreMol in its acquisition by Baxter*
• Represented Carl Zeiss in a strategic collaboration with, and ultimate acquisition of, Oraya Therapeutics*
• Represented Entellus Medical in its acquisition of CogENT Therapeutics assets* 
• Represented Urban Decay in its acquisition by L’Oreal* 
• Represented SVOX in its acquisition by Nuance*

Venture Financings:

• Represented PartsTech in connection with its $35m Series C financing*
• Represented General Catalyst in its Series B investment in Helsing*
• Represented Casana Health in its $30m Series B Preferred Stock Financing* 
• Represented argenx BV in its investment in OncoVerity*
• Represented Podimetrics in its $45m Series C Preferred Stock Financing* 
• Represented Luminopia in its $16m Series A Preferred Stock Financing*
• Represented VideaHealth in its $20m Sereis A Preferred Stock Financing* 
• Represented Probably Genetic in its $11m Series A Preferred Stock Financing*
• Represented InGeneron in its $43m Series D Preferred Stock Financing* 
• Represented Melodi Health in its $10m Series A Preferred Stock Financing*
• Represented BASF in a $50m equity investment and collaboration with Sion Power* 
• Represented Allianz in Lemonade’s $300m Series D Preferred Stock Financing* 
• Represented Allianz in its $58m preferred stock investment in American Well*

Prior to joining Goodwin, Michael was a partner at Cooley.